Stifel Financial Corp Has $776,000 Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Stifel Financial Corp lowered its stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 11.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,761 shares of the company’s stock after selling 17,975 shares during the period. Stifel Financial Corp owned approximately 0.21% of Treace Medical Concepts worth $776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Quarry LP acquired a new stake in shares of Treace Medical Concepts in the 3rd quarter worth about $38,000. HighTower Advisors LLC purchased a new stake in shares of Treace Medical Concepts in the third quarter worth approximately $58,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Treace Medical Concepts by 243.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,613 shares of the company’s stock valued at $62,000 after purchasing an additional 7,522 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Treace Medical Concepts during the third quarter valued at approximately $75,000. Finally, Walleye Capital LLC bought a new stake in Treace Medical Concepts during the third quarter worth $75,000. Institutional investors own 84.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on TMCI. Truist Financial raised their price target on shares of Treace Medical Concepts from $7.00 to $8.40 and gave the company a “hold” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $8.00 target price on shares of Treace Medical Concepts in a research report on Tuesday, December 17th. Finally, Stifel Nicolaus upped their target price on Treace Medical Concepts from $7.00 to $8.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.88.

Treace Medical Concepts Stock Up 0.1 %

TMCI opened at $6.97 on Wednesday. Treace Medical Concepts, Inc. has a 12 month low of $3.92 and a 12 month high of $15.98. The company has a market cap of $434.21 million, a PE ratio of -7.04 and a beta of 0.66. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $6.97 and a 200 day moving average of $6.49.

Treace Medical Concepts (NASDAQ:TMCI) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Treace Medical Concepts had a negative net margin of 30.33% and a negative return on equity of 51.12%. The company had revenue of $45.09 million during the quarter, compared to analysts’ expectations of $43.48 million. During the same quarter in the previous year, the company earned ($0.28) earnings per share. Treace Medical Concepts’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, sell-side analysts expect that Treace Medical Concepts, Inc. will post -0.92 EPS for the current year.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.